Paper12840682
A pilot trial of Saccharomyces boulardii in ulcerative colitis.
Guslandi M and 2 others. Eur J Gastroenterol Hepatol, 2003. Cited by 239 papers, by iCite.
Cite this record
ConductScience Library. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Papers, record 12840682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12840682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colitis, Ulcerative | Major topic |
| Probiotics | Major topic |
| Saccharomyces | Major topic |
| Adult | |
| Anti-Inflammatory Agents, Non-Steroidal | |
| Combined Modality Therapy | |
| Female | |
| Humans | |
| Male | |
| Mesalamine | |
| Middle Aged | |
| Pilot Projects | |
| Remission Induction |
Source PubMed
Cited by94
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 239 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941735 | Surface Display of an Anti-CD3 scFv by Saccharomyces boulardii and Its Effect on DSS-Induced Colitis in Mice. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941735 | PubMed |
| 42404519 | Protein-losing enteropathy after the Fontan procedure - A cardiologist's and gastroenterologist's perspective. | Ann Pediatr Cardiol | 2026 | https://conductscience.org/library/papers/42404519 | PubMed |
| 42377935 | Yeasts in the gastrointestinal tract. | FEMS Yeast Res | 2026 | https://conductscience.org/library/papers/42377935 | PubMed |
| 41749264 | Cross-kingdom microbial interactions in the gut during inflammatory bowel disease. | J Transl Med | 2026 | https://conductscience.org/library/papers/41749264 | PubMed |
| 41176278 | Dietary and Lifestyle Risk Factors in Primary Sclerosing Cholangitis: In Search of Mechanistic Explanations and Health Improvement. | J Nutr | 2025 | https://conductscience.org/library/papers/41176278 | PubMed |
| 40885775 | Engineered spermidine-secreting Saccharomyces boulardii ameliorates colitis and colon cancer in mice. | Sci Rep | 2025 | https://conductscience.org/library/papers/40885775 | PubMed |
| 40872558 | Saccharomyces boulardii CNCM I-745 Supernatant Improves Markers of Gut Barrier Function and Inflammatory Response in Small Intestinal Organoids. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40872558 | PubMed |
| 40806413 | The Human Mycobiome: Composition, Immune Interactions, and Impact on Disease. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806413 | PubMed |
| 40624229 | Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. | Nat Rev Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/40624229 | PubMed |
| 40530243 | Multi-step pathway engineering in probiotic Saccharomyces boulardii for abscisic acid production in the gut. | Metab Eng Commun | 2025 | https://conductscience.org/library/papers/40530243 | PubMed |
| 40383233 | Enabling technologies for in situ biomanufacturing using probiotic yeast. | Adv Drug Deliv Rev | 2025 | https://conductscience.org/library/papers/40383233 | PubMed |
| 40065908 | Saccharomyces boulardii Alleviates Colitis by Regulating FXR-NLRP3 Mediated Macrophage Pyroptosis. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/40065908 | PubMed |
| 39770617 | Heterologous Expression of the Antiviral Lectin Griffithsin in Probiotic Saccharomyces boulardii and In Vitro Characterization of Its Properties. | Microorganisms | 2024 | https://conductscience.org/library/papers/39770617 | PubMed |
| 39193472 | The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections. | Oxf Open Immunol | 2024 | https://conductscience.org/library/papers/39193472 | PubMed |
| 38752748 | Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance. | Appl Environ Microbiol | 2024 | https://conductscience.org/library/papers/38752748 | PubMed |
| 38585636 | Probiotics for inflammatory bowel disease: Is there sufficient evidence? | Open Life Sci | 2024 | https://conductscience.org/library/papers/38585636 | PubMed |
| 38409485 | A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease. | Indian J Gastroenterol | 2024 | https://conductscience.org/library/papers/38409485 | PubMed |
| 37935653 | Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease. | Intest Res | 2024 | https://conductscience.org/library/papers/37935653 | PubMed |
| 36651453 | Could paraprobiotics be a safer alternative to probiotics for managing cancer chemotherapy-induced gastrointestinal toxicities? | Braz J Med Biol Res | 2023 | https://conductscience.org/library/papers/36651453 | PubMed |
| 36565724 | Fungal infections and the fungal microbiome in hepatobiliary disorders. | J Hepatol | 2023 | https://conductscience.org/library/papers/36565724 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12840682
GET https://conductscience.org/api/papers/v1/12840682/cited_by?page=2